Pure Global AI
NCT06047275Recruitment Completed

HCV Microfluidic Diagnostics

Development of Point-of-care and Wearable Sensors for Hepatitis C Diagnostics
University of HullClinicalTrials.gov
Verified
Study focus
Disease/Condition
Hepatitis C
Study type
Observational
Sponsor & location
Primary sponsor
University of Hull
Location
Kingston upon Hull, United Kingdom
Timeline & enrollment
Phase
N/A
Start date
May 01, 2023
End date
May 31, 2024
Enrollment
20 participants
Primary outcome

Positivity

Summary

Hepatitis C diagnostic devices have been developed at the University of Hull to detect and
 quantify the Hepatitis C virus in patients' plasma and serum samples. This study aims to test
 the new point-of-care devices that are designed to be low cost and user-friendly.
 
 Excess, stored, HCV patients' plasma, serum and blood samples will be supplied by the
 Virology laboratory (Hull University Teaching Hospital's Trust; HUTH). These samples were
 taken and analysed as part of patients' clinical monitoring, and are stored prior to disposal
 in the Virology laboratory. The proposed study will use the samples in a fully anonymised
 manner.

ICD-10 classifications
Acute hepatitis CChronic viral hepatitis CViral hepatitisChronic viral hepatitisUnspecified viral hepatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06047275
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06047275 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Hull and is currently Recruitment Completed. The study focuses on Hepatitis C. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.